TLOG (TetraLogic Pharmaceuticals) Debt-to-EBITDA : -0.84 (As of Sep. 2016)

What is TetraLogic Pharmaceuticals Debt-to-EBITDA?

TetraLogic Pharmaceuticals TLOG Debt-to-EBITDA is -0.84 as of Sep. 2016.

Debt-to-EBITDA measures a company's ability to pay off its debt.

TetraLogic Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $30.81 Mil. TetraLogic Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2016 was $-36.73 Mil. TetraLogic Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2016 was -0.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for TetraLogic Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

TLOG's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.15
* Ranked among companies with meaningful Debt-to-EBITDA only.

TetraLogic Pharmaceuticals (OTCPK:TLOG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

TetraLogic Pharmaceuticals Debt-to-EBITDA Related Terms

TetraLogic Pharmaceuticals Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals Debt-to-EBITDA Chart

TetraLogic Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-EBITDA

0.00

-0.30

0.00

-0.84

-0.66

TetraLogic Pharmaceuticals Quarterly Data
	Dec11	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-EBITDA	Get a 7-Day Free Trial													-0.78	-0.56	-0.78	-1.49	-0.84

TLOG vs ARGSQ, GTHR, SOAN: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Debt-to-EBITDA falls into.

Save Embed

TetraLogic Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

TetraLogic Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	28.279)	/	-43.152
	=	-0.66

TetraLogic Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2016 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	30.809)	/	-36.732
	=	-0.84

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2016) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -0.84 mean?

TetraLogic Pharmaceuticals (TLOG) has a Debt-to-EBITDA of -0.84 as of Sep. 2016. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TetraLogic Pharmaceuticals.

Is TetraLogic Pharmaceuticals' Debt-to-EBITDA too high?

TetraLogic Pharmaceuticals' current Debt-to-EBITDA is -0.84.

How does TetraLogic Pharmaceuticals' Debt-to-EBITDA compare to ARGSQ and GTHR?

TetraLogic Pharmaceuticals' Debt-to-EBITDA of -0.84 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TetraLogic Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TetraLogic Pharmaceuticals's current Debt-to-EBITDA is -0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is TetraLogic Pharmaceuticals stock overvalued right now?

TetraLogic Pharmaceuticals (TLOG) has a current Debt-to-EBITDA of -0.84. The current Debt-to-EBITDA is -0.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current Debt-to-EBITDA is -0.84 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ARGSQ GTHR SOAN CTBO BOM:524604 GWSN WAR:PFM TSXV:PBS IMUC MBVXQ NTRR STLT XSAT:EURI B HSTC BOM:506365 BOM:532041 ATMS BOM:524796 LSE:ANIC TSXV:COT

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355

Website http://www.tetralogicpharma.com

TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.